The overall age-adjusted mortality rate for co-existent pancreatic cancer and cardiovascular disease in the US increased from 26.164 in 1999 to 31.478 per 1,000,000 in 2020 (APC 0.85%).
Cohort (n=189,463)
Mortality associated with comorbid pancreatic cancer and cardiovascular disease has consistently increased in the US from 1999 to 2020, with notable disparities across sex, race, and urbanization status.
Estimación del efecto: APC 0.85% (95% CI 0.72-0.98)
Tasa de eventos absoluta: 31.478% vs 26.164%
valor p: p=< 10⁻⁶
Pancreatic cancer and cardiovascular disease are among the leading causes of death in the U.S. and may co-occur with compounding effects. This study assesses trends in mortality rates for comorbid pancreatic cancer and cardiovascular disease, along with sociodemographic disparities to better inform public health and policy efforts. A retrospective cohort study was conducted using CDC WONDER data between 1999 and 2020. Mortality for pancreatic cancer was assessed using ICD-10 code C25 with I00-I99 for any cardiovascular-related death. Joinpoint regression software was used to assess mortality trends overall and across strata of race, sex, and urbanization status. Age-adjusted mortality rate (AAMR) per 1,000,000 was examined on a year-by-year and demographic basis by assessing annual percent change (APC) with confidence intervals and p-values. Between 1999 and 2020, 189,463 deaths were associated with both cardiovascular death and pancreatic cancer. Overall age-adjusted mortality rate (AAMR) per 1,000,000 increased from 26.164 in 1999 to 31.478 in 2020 (APC = 0.85%, CI = 0.72–0.98%, p < 10⁻⁶). Males consistently had higher mortality rates than females, with both groups showing significant increases (APC male =0.86%, APC female =0.94%, p < 10⁻⁶). White individuals had higher absolute mortality rates, whereas Black/African-American individuals demonstrated a greater relative increase over time (APC = 1.38% vs. 1.10%; p < 10⁻⁶ for both). Metropolitan residents had consistently lower mortality rates than non-metropolitan residents, but metropolitan residents experienced a sharper increase (APC metro =0.84%, APC non−metro =0.63%, p < 10⁻⁶). Pancreatic cancer-associated cardiovascular mortality has consistently increased in the United States from 1999 to 2020. There were notable demographic disparities which could provide insight towards targeted interventions for long-term mortality decrease.
Ponnada et al. (Wed,) conducted a cohort in Co-existent pancreatic cancer and cardiovascular disease (n=189,463). Calendar year (1999-2020) vs. 1999 (baseline) was evaluated on Age-adjusted mortality rate (AAMR) per 1,000,000 (APC 0.85%, 95% CI 0.72-0.98, p=< 10⁻⁶). The overall age-adjusted mortality rate for co-existent pancreatic cancer and cardiovascular disease in the US increased from 26.164 in 1999 to 31.478 per 1,000,000 in 2020 (APC 0.85%).